Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Congenica

Congenica
2012 FOUNDED
PRIVATE STATUS
71-80 EMPLOYEES
Series B LATEST DEAL TYPE
$30.3M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of a clinical genome interpretation software designed to identify genetic diseases in patients. The company's clinical genomic analytics platform processes genomic datasets to detect mutations by filtering clinically relevant variants and deep clinical phenotyping, enabling clinicians and researchers to interrogate the human genome to identify disease-causing variants.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Primary Office
  • Wellcome Genome Campus
  • Cambridge CB10 1DR
  • England, United Kingdom

+44 01223 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Congenica’s full profile, request a free trial.

Congenica Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 30-Apr-2019 $30.3M 000.00 0000 Completed Generating Revenue
6. Grant 29-Sep-2015 00000 00.000 Completed Generating Revenue
5. Early Stage VC (Series A) 01-Apr-2015 00.000 00.000 00.00 Completed Generating Revenue
4. Grant 11-Mar-2015 00.000 00.000 Completed Startup
3. Seed Round 05-Dec-2014 00.000 00.000 Completed Startup
2. Seed Round 01-Oct-2014 $814K $814K 00.000 Completed Startup
1. Grant 02-May-2014 $570K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Congenica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
A Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
A Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
A Ordinary 2,553,500 $0.001493 $0.29 $0.29 1x $0.29 20.88%
Ordinary 500,000 $0.001493 $0.01 $0.01 1x $0.01 4.09%
To view this company’s complete Cap Table, request access »

Congenica Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genalice Formerly PE-Backed Harderwijk, Netherlands 00 000000 - 000
000000 00000000 Formerly VC-backed Hercules, CA 00 00.000 000000&0 00.000
000000 (0000 00000 Venture Capital-Backed Bangalore, India 000 000.00 0000000000 0 000.00
000000 00000000 Venture Capital-Backed Oakland, CA 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed Ann Arbor, MI 0 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Congenica Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BGI PE-Backed Company Minority 000 0000 000000 0
Digital China Health Corporation Minority 000 0000 000000 0
Future Planet Capital Growth/Expansion Minority 000 0000 000000 0
Healthlink Capital Other Minority 000 0000 000000 0
Parkwalk Advisors Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Congenica Executive Team (16)

Name Title Board
Seat
Contact
Info
David Atkins Ph.D Chief Executive Officer & Board Member
Wendy Britten Chief Financial Officer
Nicholas Lench Ph.D Co-Founder, Chief Operating Officer, Chief Scientific Officer & Board Member
Peter Fox Chief Technology Officer
Richard Durbin Co-Founder & Informatics Director

7 Former Executives

You’re viewing 5 of 16 executives. Get the full list »

Congenica Board Members (15)

Name Representing Role Since Contact
Info
Alastair Kilgour Parkwalk Advisors Board Member 000 0000
Andrew Richards Congenica Chairman 000 0000
David Atkins Ph.D Congenica Chief Executive Officer & Board Member 000 0000
Matthew Hurles Ph.D Congenica Co-Founder, Scientific Director & Board Member 000 0000
Michael Anstey Ph.D Cambridge Innovation Capital Board Member 000 0000

8 Former Board Members

You’re viewing 5 of 15 board members. Get the full list »